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Abstract: Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan.
Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high
cost.
Results: In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV
3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin
(SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the
GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC),
column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results
showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells
Conclusion: Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and
combination of SM and its fractions with interferon will be a better option to treat HCV infection
Background
HCV is a leading cause of variety of liver diseases vary-
ing from asymptomatic condition to hepatocellular car-
cinoma. HCV affects 270 million people worldwide and
10-15 million people are the carriers of HCV in Pakistan
[1]. It was estimated by the World Health Organization
in 2004 that the annual deaths due to liver cancer
caused by HCV and cirrhosis were 308,000 and 785,000,
respectively [2]. HCV is a blood-borne pathogen, which
transmitted through parenteral exposure to contami-
nated blood or body fluids [3]. Factors most strongly
associated with HCV infection are blood transfusion
(56%), alcohol consumption (44%) and intravenous drug
abuse (31%) [3,4]. Some other risk factors include use of
inadequately sterilized medical equipment, high-risk sex-
ual behaviors, and social or cultural practices such as
body piercing, circumcision, and tattooing [5,6].
Pegylated interferon (PEG-IFN) plus Ribavirin therapy is
the current treatment for the patient with chronic hepati-
tis C. The main goal of therapy is to achieve a sustained
virological response currently defined as undetectable
HCV-RNA in peripheral blood determined with the most
sensitive polymerase chain reaction technique 24 weeks
after the end of treatment. This goal is practically equiva-
lent with eradication of HCV infection and cure of the
underlying HCV induced liver disease. This therapy cure
only half number of patients due to side effects, resistance
and high cost [7-10]. Hence, there is a need to develop
anti-HCV agents, both from herbal sources and synthetic
chemistry which are less toxic, more efficacious and cost-
effective. The present study was undertaken to study the
effect of SM and its fraction against HCV 3a core gene in
liver cells. We report here that SM and its fractions effec-
tively inhibited Core gene RNA and protein expression in
a dose-dependant manner in Huh-7 cells.
Materials and methods
Extraction of Silybum marianum
The seeds of Silybum marianum were collected from
Township market and SM was extracted as described by
Polyak [11]. Briefly, fine powder of seeds was made in a
blender. Defatted the seed powder of Silybum marianum
in n-hexane 2-3 times and extracted with aqueous acet-
one. The extract was concentrated to remove acetone,
and then washed by hexane again to remove hydrophobic
impurities. The remaining concentrate was treated with
1% NaCl solution to remove water soluble impurities.
The precipitate and solid obtained through drying were
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SM was washed with aqueous ethanol and then dried
completely to give the refined yellowish powder of SM.
Stock solution preparation
50 mg of SM was suspended in one ml of Dimethyl sulf-
oxide (DMSO) ensuring stock concentration of 50 μg/μl.
Sieving the above solution by using 0.22 um filter inside
Laminar Flow Hood, storing at -20°C.
Cell line
The Huh-7 cell line was offered by Dr. Zafar Nawaz
(Biochemistry and Molecular Biology Department,
University of Miami, USA). Huh-7 cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum & 100 IU/ml peni-
cillin & 100 μg/ml streptomycin, at 37°C in an
atmosphere of 5% CO2.
Plasmid construction
For the construction of expression plasmid, viral RNA
was extracted from 100 μl serum aliquots using Gentra
RNA isolation kit (Gentra System Pennsylvania, USA)
according to the manufacturer’s instructions. About
200 ng RNA was used for RT-PCR using the Super-
Script III one-step RT-PCR system (Invitrogen Life tech-
nologies, USA). HCV complementary DNA (cDNA)
encoding the full length Core protein (amino acid 1-191
of HCV-3a) were amplified and cloned into pCR3.1
mammalian expression plasmid (kindly provided by Dr.
Zafar Nawaz, University of Miami, USA) with FlagTAG
inserted at the 5’ end of the Core gene with EcoRV and
XbaI restriction sites.
MTT assay for toxicity
To investigate cellular toxicity, 2×10
4 cells/well was pla-
ted into 96-well plates. After 24 h, different concentra-
tions of SM were added and the plate was sealed and
kept at 37°C in an atmosphere of 5% CO
2 for 24 h.
After the herbal extracts treatment was over, removed
the media and SM. 100 μlf r e s hm e d i aa n d2 0μlo f
MTT solution (5 mg/ml in PBS) were added to all wells
in Columns 1-11. Wrapped the plate in aluminum foil
and incubated for 3-4 h at 37°C. Media was carefully
removed and added 100 μl of DMSO to dissolve the for-
mazan crystals in Columns 1-11. MTT formazan pro-
duct was determined by measuring absorbance with an
enzyme-linked immunosorbent assay (ELISA) plate
reader at a test wavelength of 570 nm and a reference
wavelength of 620 nm.
Cell viability was obtained using the following equation:
Percent cell viability = (Test 570nm − 620nm/Control 570nm − 620nm) ∗ 10
Antiviral activity of SM and its fractions against HCV 3a
core gene
For transfection studies, Huh-7 cells (5×10
4) were plated
in 24-well plates for 24 h. The medium was removed and
cells were washed with 1X PBS. Cells were transiently
transfected with expression plasmids containing HCV 3a
core gene (0.4 μg) in the presence and absence of SM, its
fractions and interferon by using Lipofectamine™ 2000
(Invitrogen life technologies, Carlsbad, CA) according to
the manufacturer’s protocol. Total RNA was extracted by
using Trizol reagent (Invitrogen life technologies, Carls-
bad, CA) according to the manufacturer’sp r o t o c o l .T o
analyze the effect of SM against HCV 3a core gene,
cDNA was synthesized with 1 μgo fR N A ,u s i n gR e v e r t
Aid TM First Strand cDNA Synthesis Kit (Fermentas, St.
Leon-Rot/Germany). Gene expression analysis was car-
ried out via PCR (Applied Biosystems Inc, USA) by using
2X PCR Mix (Fermentas). Following primers were used
for the amplification of HCV Core forward primer:
GGACGACGATGACAAGGACT; HCV core reverse:
GGCTGTGACCGTTCAGAAGT; GAPDH Forward:
ACCACAGTCCATGCCATCAC: and GAPDH reverse;
TCCACCACCCTGTTGCTGTA PCR was performed by
initial denaturation at 95°C for 5 min followed by 30
cycles, each of denaturation at 92°C for 45 s, annealing at
58°C for 45 s, and extension at 72°C for 1 min, with final
extension at 72°C for 10 min. The amplified DNA sam-
ples were analyzed on 2% agarose gel. The DNA bands
were visualized directly under the UV and the photo-
graphs of the gels were obtained with gel documentation
system.
Western Blotting
To determine the protein expression levels of HCV 3a
core, the transfected and non-transfected cells were
lysed with ProteoJET mammalian cell lysis reagent (Fer-
mentas, Canada). Equal amounts of total protein were
subjected to electrophoresis on 12% SDS-PAGE and
electrophoretically transferred to a nitrocellulose mem-
brane following the manufacturer’s protocol (Bio-Rad,
CA). After blocking non-specific binding sites with 5%
skimmed milk, blots were incubated with primary
monoclonal antibodies specific to HCV Core and
GAPDH (Santa Cruz Biotechnology Inc, USA) and sec-
ondary Horseradish peroxidase-conjugated anti-goat
anti-mouse antibody (Sigma Aldrich, USA). The protein
expressions were evaluated using chemiluminescence’s
detection kit (Sigma Aldrich, USA).
Purification of SM fractions
Purification of SM fractions was done through thin
layer chromatography. Briefly, 1% sample solution was
prepared in 5 ml solvent and was filtered. Took a TLC
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Page 2 of 7card and cut it in 10 cm length and 5 cm width. Small
spot of sample was marked on plate. Dried and placed
it in chromatography tank having ethyl acetate: chloro-
form (60: 40) as mobile phase and allowed it to run
for one and a half hour. Then, solvent front was
marked and chromatogram was dried. TLC chromato-
gram was observed under UV lamp at wavelength of
254 nm and 366 nm. Separation of components was
good and spots of different colors were observed. Pat-
tern of spots was recorded and Rf value of each spot
was determined.
Results
Toxicological analysis of SM
Before starting the antiviral screening against HCV, toxi-
cological effect of SM was determined through MTT
cell proliferation assay. The MTT substance is reduced
by mitochondrial succinic dehydrogenases in living cells
to purple formazan crystals that are not soluble in aqu-
eous water. The absorption of dissolved formazan in the
visible region correlates with the number of alive cells
[12]. Figure 1 shows cytotoxicity analysis of SM at dif-
ferent doses and demonstrates that Huh7 cells viability
is unaffected by concentrations up to 20 μg. However,
when the concentration exceeded 40 to 80 μg, toxic
effect in liver cells were observed. The data was verified
by microscopic examination of cells and standard trypan
blue dye measurement, which demonstrates that SM has
no toxic effect at a concentration of 20 μg.
Antiviral effect of SM against HCV 3a Core gene
To determine the antiviral effect against HCV core gene,
Huh-7 cells were transfected with HCV core gene in the
presence and absence of different concentrations of SM
and interferon. After 24 h, RNA was extracted through
Triazol (Invitrogen). cDNA were generated by oligo dT
primer. cDNA was amplified by PCR using primers spe-
cific to the HCV core gene of 3a genotype. Amplifica-
tion of GAPDH mRNA served as an internal control.
Figure 2 demonstrates that SM inhibits HCV RNA
expression in a dose-dependent manner, while GAPDH
mRNA expression remains unaffected by the addition of
the compound. Moreover, SM inhibits HCV core
expression or function similar to interferon. This may
be due to direct effect of SM against HCV 3a core or
activation of JAK/STAT pathway.
Purification of different fractions of SM by thin layer
chromatography
Crude extract of SM was fractioned by thin layer chro-
matography (TLC). SM separates in to four components
S1, S2, S3 and S4 in solvent (ethyl acetate: chloroform)
with Rf value 0.51, 0.40. 0.64 and 0.75 respectively. Pur-
ity of each fraction was checked by HPLC (Figure 3).
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Figure 1 Toxicity of Silymarin through MTT cell proliferation assay. Huh-7 cells were plated at the density of 2 × 10
4 in 96 well plates. After
24 h cells were treated with different concentrations of SM and control consisted of solvent in which compound dissolved. After 24 h
incubation period add MTT solution to all wells and incubated for 3-4 h at 37°C. Viable cells convert MTT to purple formazan crystal. Added
DMSO to dissolve the formazan crystals and read absorbance at 570 nm and 620 nm.
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silica and dried the sample by mixing the silica. Allowed
the solvent (ethyl acetate: chloroform 60: 40) to flow
down with 1 ml/min. Fractions were collected after half
an hour. Then fractions were combined after checking
each fraction in TLC plate at 254 wavelength to obtain
purely separate components (S1, S2, S3, and S4). The
individual fraction was then solubilized in DMSO, and
tested for antiviral screening against HCV. Western
blotting results showed a dramatic reduction at the pro-
tein level of HCV core protein in cells treated with SM
and its fractions S1 and S2; whereas the expression
levels of GAPDH protein remained the same in control
verses treated cells (Figure 4).
Discussion
HCV infection is a serious global health problem that
affects 180 million people worldwide and 10 million
people in Pakistan. Currently, no vaccine is available for
prevention of HCV infection due to high degree of
strain variation. The current treatment with PEG-INFa
in combination with ribavirin is costly, has significant
side effects and fail to cure about one half of all infec-
tions [13,14]. Hence, there is a need to develop other
anti-HCV agents, which are less toxic, more efficacious
and cost-effective. It is well known that medicinal plants
have been used for centuries against different diseases
including viral diseases and were therefore, used during
the last century to identify, isolate and purify new com-
pounds to treat viral and bacterial diseases. Many tradi-
tional medicinal plants and herbs were reported to have
strong antiviral activity against DNA and RNA viruses
by inhibiting virus replication, interfering with virus-to-
cell binding and immunomodulation actions [15,16].
HCV structural proteins (core, E1 and E2) and non-
structural proteins (NS3 protease and NS5B RNA-
dependent RNA polymerase) are potent molecular
targets of new antiviral compounds.
Silybum marianum is a flavolignin commonly known as
‘milk thistle’. Silybum marianum has been shown to have
clinical applications in the treatment of toxic hepatitis,
fatty liver, cirrhosis, ischemic injury, radiation toxicity, and
viral hepatitis. SM has been found to suppress nuclear fac-
tor kappa B (NF kB) dependent gene expression and also
has inhibitory action on inflammatory and cytotoxic cas-
cade of events induced by the viral infection (Saller et al.,
2001). SM has anti-oxidative effect by inhibiting free radi-
cals such as superoxide radical, hydroxyl radical (OH),
hydrogen peroxide (H2O2), and lipid peroxide radicals
[17]. SM has been shown to inhibit the growth of endothe-
lial [18], lung tumor [19], prostate cancer [20], and human
hepatoma HepG2 and Hep3B cells. The anti-proliferative
actions of SM are due to inhibition of signaling pathways
that regulate the cell cycle including Akt and cyclin-
dependent kinases. SM is a complex mixture of four flavo-
nolignan isomers, namely silybin, isosilybin, silydianin and
silychristin with an empirical formula C25H22O10. Silybin
is the major and most active component and represents
about 60-70 percent, followed by silychristin (20%), silydia-
nin (10%), and isosilybin (5%) [21]. SM plays an important
part in modulating cell membrane and membrane recep-
tors by inhibiting the binding of epidermal growth factor
[22]. Thus, SM shows hepatoprotective effect by altera-
tions in the hepatic membrane. However, the results, of
different clinical trials show that SM reduces liver enzymes
such as ALT and AST associated with hepatitis [23].
Figure 2 Antiviral effect of SM against HCV core gene in Liver cells. Huh-7 cells were transfected with Core in the presence and absence of
different concentration of SM and interferon. After 24 h incubation period, total RNA was extracted and the levels of HCV core gene were
determined by RT-PCR.
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dants including SM also reduced ALT levels in 44% of
patients, and reduced viral load in 25% of patients [24].
SM has anti-proliferative properties due to the modulation
of specific signaling pathways, transcription factors and
gene expression [25]. SM also effect on hepatic stellate
cells (HSC) and decreases HCV-induced fibrosis [26].
A recently published clinical trial, shows that high doses of
intravenous silibinin results potent antiviral activity against
HCV infected patient [27].
HCV Core protein modulates gene transcription, cell
proliferation, cell death and cell signaling, interferes
(A)  
(B) 
 
 
(C) 
Figure 3 TLC and HPLC chromatogram of SM Fractions. (A) Ran SM extract in TLC plate. Analyzed the sample at UV light of 254 wavelength.
It separates into four components S1, S2, S3, and S4 in solvent (ethyl acetate: chloroform 60:40) with Rf values 0.51, 0.40, 0.64 and 0.75
respectively. (B) HPLC Chromatogram of S1 fraction. (C) HPLC chromatogram of S2 fraction.
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response [28] leading to oxidative stress, liver steatosis
and eventually hepatocellular carcinoma [29]. Core pro-
tein is also able to up-regulate cyclooxygenase-2 (Cox-2)
expression in hepatocytes derived cells, providing a
potential mechanism for oxidative stress [30]. The
expression of Cox-2 in HCC was found to correlate
with the levels of several key molecules implicated in
carcinogenesis such as inducible nitric oxide synthetase
(iNOS), activate vascular endothelial growth factor
(VEGF) and phosphorylated Akt (p-Akt) [31,32]. In this
study, SM was examined for toxicological analysis in
Huh-7 line. Our data show that SM is non toxic at a
concentration up to 20 μg but when exceed from 30 μg
SM show toxic effect in both liver and fibroblast cells
(Figure 1). The study of Polyak et al also agreed with
the statement that SM has non toxic up to 20 μgc o n -
centration [11]. After toxicological analysis, antiviral
effect against HCV core gene of 3a genotype was
analyzed and our results showed that SM resulted in
dose-dependent inhibition of HCV core gene similar to
interferon alpha 2a (Figure 2). This may be due to sti-
mulation of interferon pathway by phosphorylation of
Stat1 on tyrosine and serine [11]. SM may have effective
on hepatocyte membranes, interferon receptor, inhibit
of negative regulators of the Jak-Stat pathway such as
SH2-containing phosphatases, the protein inhibitors of
activated STATs, or the suppressors of cytokine signal-
ing proteins such as SOCS 1 and SOCS 3 proteins [33].
Studies in cell culture models have suggested a role for
SOCS3 in HCV IFN resistance. HCV core protein over-
expression has been reported to induce SOCS3 in cell
culture models, resulting in impaired IFN signaling.
HCV replicon cells resistant to IFN therapy have been
shown to produce higher levels of SOCS3; inhibition of
SOCS3 expression results in production of interferon
[34]. Furthermore, several in-vivo studies have shown
that hepatic SOCS3 expression is associated with
response to IFN treatment. Other possible mechanism
could involve such as IRF3 or IRF9 and MAPK path-
ways [35]. In order to identify the active ingredient
against HCV, SM was fractioned by thin layer chroma-
tography (TLC), column chromatography and HPLC.
Two fractions (S1 and S2) out of four showed antiviral
effect against HCV core gene expression or function.
These results showed that SM contains potential phyto-
chemicals such as S1 and S2 and combination of these
agents with interferon is helpful to cure HCV infection.
Abbreviations
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